Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indoco Remedies gets...

    Indoco Remedies gets two minor observations from USFDA for Goa plants

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-25T09:07:37+05:30  |  Updated On 17 Aug 2021 12:16 PM IST
    Mumbai: Drug firm Indoco Remedies on Thursday said it has received two minor observations from the US health regulator for its Goa-based two plants. The US Food and Drug Administration (USFDA) inspected Indoco's Sterile facility (Plant II) and Solid Dosages facility (Plant III) situated at L-32/33/34 Verna Industrial Estate, Goa from 14th November till 21st November 2018. The inspection concluded with Indoco receiving 2 minor observations, none of which are a repeat in nature.

    The facility had received a Warning Letter from the USFDA in March 2017.

    The Company said it is in the process of responding to the observations within the stipulated time of 15 days. The EIR will be issued by the USFDA subsequently, it added.

    "This positive development will now pave the way for approval of our pending ANDAs with a consequent boost to revenues from the US market. Indoco is committed to its philosophy of highest quality in manufacturing, operations, systems integrity and cGMP culture", said Aditi Kare Panandikar, Managing Director of Indoco Remedies Ltd.

    "The inspection concluded with the company receiving two minor observations, none of which are a repeat in nature," Indoco Remedies said in a regulatory filing.

    Headquartered in Mumbai, Indoco Remedies is a fully integrated, research-oriented pharma Company and has nine manufacturing facilities. It has a presence across 55 countries. Indoco, a USD 161 million Company, employs over 5500 people including more than 300 skilled scientists.

    In 1945, a Goan entrepreneur Mr Govind Ramnath Kare, who was in the business of wholesale and retail trade of pharmaceuticals, started a firm which he named Indo Continental Trading Company.

    The principal business of this firm was to import pharmaceutical formulations from Europe and distribute them in Western India.

    However in 1947, after India became independent, the new Government in its bid to encourage indigenous manufacturing of medicines banned the import of several formulations. Mr G.R. Kare instead of being discouraged decided to venture into manufacturing of pharmaceuticals.

    Accordingly, on 23rd August 1947, a week after India's independence, a new Company was founded with the intent to manufacture and sell pharmaceutical formulations.

    Thus, Indo Continental Trading Company became Indoco Remedies Limited.

    Also Read: Indoco Remedies Goa unit receives approval from UK health regulator
    aditi kare panandikarBSEDrug firmEIRGoaIndocoIndoco RemediesinspectiononservationUSFDA
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok